Treatment of RB1-intact cancers with CDK4/6 inhibitor combination therapy.

被引：0
|
作者：
Takahashi, Chiaki [1 ]
机构：
[1] Kanazawa Univ, Canc Res Inst, Kanazawa, Ishikawa, Japan
来源：
CANCER RESEARCH | 2021年 / 81卷 / 13期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1001
引用
收藏
页数：2
相关论文
共 50 条
  • [31] A review of phase 3 clinical trials of CDK4/6 inhibitor combination therapy in premenopausal women.
    Yardley, Denise A.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [32] PARP and CDK4/6 Inhibitor Combination Therapy Induces Apoptosis and Suppresses Neuroendocrine Differentiation in Prostate Cancer
    Wu, Cheng
    Peng, Shan
    Pilie, Patrick G.
    Geng, Chuandong
    Park, Sanghee
    Manyam, Ganiraju C.
    Lu, Yungang
    Yang, Guang
    Tang, Zhe
    Kondraganti, Shakuntala
    Wang, Daoqi
    Hudgens, Courtney W.
    Ledesma, Debora A.
    Marques-Piubelli, Mario L.
    Torres-Cabala, Carlos A.
    Curry, Jonathan L.
    Troncoso, Patricia
    Corn, Paul G.
    Broom, Bradley M.
    Thompson, Timothy C.
    MOLECULAR CANCER THERAPEUTICS, 2021, 20 (09) : 1680 - 1691
  • [33] A review of phase III clinical trials of CDK4/6 inhibitor combination therapy in premenopausal women.
    Yardley, Denise A.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (34)
  • [34] CDK4/6 and autophagy inhibitors synergize to induce senescence in cancers with an intact G1/S checkpoint
    Vijayaraghavan, Smruthi
    Karakas, Cansu
    Chen, Xian
    Doostan, Iman
    Raghavendra, Akshara S.
    Yi, Min
    Amaravadi, Ravi
    Hunt, Kelly
    Tripathy, Debu
    Keyomarsi, Khandan
    CANCER RESEARCH, 2017, 77
  • [35] CDK4/6 inhibitor and radiation therapy in malignant pleural mesothelioma.
    Matsumoto, Seiji
    Fukuda, Akihiro
    Nakamichi, Toru
    Nakamura, Akifumi
    Kuroda, Ayumi
    Hashimoto, Masaki
    Takuwa, Teruhisa
    Kondo, Nobuyuki
    Hasegawa, Seiki
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [36] PALBOCICLIB Cyclin CDK4/CDK6 Inhibitor Oncolytic
    Haddley, K.
    DRUGS OF THE FUTURE, 2013, 38 (11) : 745 - 755
  • [37] The identification of combinations for the CDK4 and CDK6 inhibitor, abemaciclib
    Gong Xueqian
    Chio, Li-Chun
    Webster, Yue
    Lallena, Maria Jose
    Boehnke, Karsten
    Torres, Raquel
    Iversen, Phil
    De Dios, Alfonso
    Smith, Ian
    Reinhard, Christoph
    Peng, Sheng-Bin
    Dempsey, Jack
    Burke, Teresa
    Chen, Shih-Hsun
    Stewart, Trent
    Beckmann, Richard
    Wu, Wenjuan
    Buchanan, Sean G.
    MOLECULAR CANCER RESEARCH, 2016, 14
  • [38] Preclinical head-to-head comparison of CDK4/6 inhibitor activity toward CDK4 vs CDK6
    Delach, Scott
    Caponigro, Giordano
    CANCER RESEARCH, 2021, 81 (04)
  • [39] Cdk4/6 inhibitor activity in metastatic bladder cancer cell lines is independently of RB1 status
    Castellano, D.
    Rubio, C.
    Lopez-Calderon, F.
    Segovia, C.
    Duenas, M.
    Martinez-Fernandez, M.
    Otero, I.
    Manneh, R.
    De Velasco, G.
    Paramio, J.
    ANNALS OF ONCOLOGY, 2016, 27
  • [40] Factors influencing CDK4/6 inhibitor adherence
    Clement, Navya
    Stutsky, Martha
    Gurubaran, Shreevidya Periyasamy Shanmugavel
    Smullen, Kate
    Argeros, Andrew
    Wolfe, Diane
    Donovan, Jennifer
    CURRENT MEDICAL RESEARCH AND OPINION, 2022, 38 : 24 - 24
12345